Investor presentation for june 23
Formal approval from CCI on stake sale to Advent:
CCI approves Berhyanda’s acquisition of Suven Pharma - The Hindu BusinessLine
Thanks,
Tarun
Unlikely move in stock price today. up 5% closing more or less at open. After the confirmation, should receive meaningful news on the company’s future from Advent. Either on merger or future operations.
After the completion of this transaction, it will be prudent to merge ZCL and RA Fine into Suven Pharma. will be interesting to see the merger ratio/buy price when it happens.
New Board for Suven Pharma is announced. The Pharma Industry veteran’s are going to run the show whereas Mr. Jasti is going to be on advisory board.
Press Release with Board Member’s Details - https://www.bseindia.com/xml-data/corpfiling/AttachLive/47212d9d-88c4-4456-a037-77a9cd8bdfcb.pdf
Open offer is announced today @ Rs. 495 per share, significantly below the CMP. Looks like Advent is not interested in acquiring any additional shares and this open offer is only to complete legal formalities.
Company has released the new investor presentation. Adding the slide for H2FY24 and medium term outlook here.
Full Investor Presentation is here
I’m sharing a GROUND report by Botlivala & Karani Securities Pvt. Ltd. on their visit to the Hyderbad Pharma plants. It also covers Suven Pharma.
Pharmaceutical - Hyderabad Visit - Flash Note - 01 Apr 24.pdf (347.4 KB)
I hope you find it useful.
dr.vikas
Sharing an interest article on the Indian CDMO landscape.
Fortune India: Business News, Strategy, Finance and Corporate Insight